This month, a series of events will gather a large range of stakeholders (academia, industry, funders, policy-makers, patient organisations) to discuss the future of personalised medicine in Europe, USA and beyond.
A delegation from EATRIS Coordination team will be present as attendee and speaker to highlight the role of pan-European medical research infrastructures in shaping the field and laying the foundations for robust and successful healthcare systems. Particularly, EATRIS will raise the voice of the translational research community and advocate about the importance to join forces and solve the scientific challenges in the field of biomarker development and validation.
Personalised medicine is key scientific priority of EATRIS Strategic Plan 2019-2022, soon to be released. According to Toni Andreu, EATRIS Scientific Director, ” the progress of Personalised Medicine depends on our ability to improve the translational medicine process. Patient-targeted interventions require the highest level of quality and reproducibility at every single step of the translational medicine pipeline, from the moment when the scientific discovery is made to the moment this discovery has been transformed into a novel drug that can be administered to the right patient, at the right time and the right dose”.
Toni Andreu will be present at the following meetings:
- 14th Personalized Medicine Conference: Preparing the New Possible, organised by the Personalized Medicine Coalition (PMC), Boston, USA, November 14-15 2018. Toni Andreu will chair a session on November 14th, titled: “Shifting Systems: Identifying the Common Challenges and Notable Achievements of Government Efforts to Advance Personalized Medicine” (Part 1: The Infrastructure for Innovation)
- ICPerMed Conference, Berlin, November 20-21 2018.
More information – Last chance to register until November 9!
- 2nd European Alliance for Personalised Medicine (EAPM) Congress: Forward as one, Integrating Innovation into Europe’s Healthcare Systems, Milan, November 26-28 2018. Toni Andreu will be panelist on November 27th for the session: “Genomic Track: Why Should the EU Take the Lead?”
We look forward to meeting you there!